Neuropathic pain is refractory against conventional analgesics, and thus novel medicaments are desired for the treatment. Glycinergic neurons are localized in specific brain regions, including the spinal cord, where they play an important role in the regulation of pain signal transduction. Glycine transporter (GlyT)1, present in glial cells, and GlyT2, located in neurons, play roles in modulating glycinergic neurotransmission by clearing synaptically released glycine or supplying glycine to the neurons and thus could modify pain signal transmission in the spinal cord. In this study, we demonstrated that i.v. or intrathecal administration of GlyT1 inhibitors, cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl methyl)amino methylcarboxylic acid (ORG25935) or sarcosine, and GlyT2 inhibitors, 4-benzyloxy-3,
or knockdown of spinal GlyTs by small interfering RNA of GlyTs mRNA produced a profound antiallodynia effect in a partial peripheral nerve ligation model and other neuropathic pain models in mice. The antiallodynia effect is mediated through spinal glycine receptor ␣3. These results established GlyTs as the target molecules for the development of medicaments for neuropathic pain. However, these manipulations to stimulate glycinergic neuronal activity were without effect during the 4 days after nerve injury, whereas manipulations to inhibit glycinergic neuronal activity protected against the development of allodynia in this phase. The results implied that the timing of medication with their inhibitors should be considered, because glycinergic control of pain was reversed in the critical period of 3 to 4 days after surgery. This may also provide important information for understanding the underlying molecular mechanisms of the development of neuropathic pain.
Neuropathic pain arising from peripheral or spinal nerve injury and diabetes or infection with herpes virus is a result of the final product of an altered peripheral, spinal, and supraspinal process for which the usual analgesics are not effective and novel analgesics are desired. Recent progress of research on the underlying mechanism of the pathology revealed more complexity, depending on the cause and stage of ongoing neuropathy. Among various mechanisms involved in the pathology, alterations of synaptic transmission within the spinal cord dorsal horn as well as peripheral nerves after peripheral nerve injury play key roles. In addition to the activation of stimulatory spinal neurotransmission, disinhibition of inhibitory neurotransmission has been implicated in the generation of inflammatory and neuropathic pain (Woolf and Mannion, 1999) . Glycine as well as GABA serve as major inhibitory neurotransmitters in the spinal cord of vertebrates. In fact, relief from glycinergic inhibition by an inhibThis work was supported in part by grants-in aid for Scientific Research (B) of Japan and by a grant from the Japanese Smoking Research Association, and it was carried out with equipment from the Research Facilities for Laboratory Animal Science.
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itor of glycine release (Ito et al., 2001) or blockers of glycine receptors (Sivilotti and Woolf, 1994; Sherman et al., 1997; Loomis et al., 2001; Gomeza et al., 2003a) in the dorsal horn can elicit tactile allodynia, a major symptom of neuropathic pain. Recent studies suggested that reduction of the chloride gradient across the neuronal membrane, which in turn leads to reduction of anion reversal potential, occurred in neurons of lamina I of the superficial dorsal horn after peripheral nerve injury (Coull et al., 2003) . The change in the driving force means that both glycine and GABA A receptor-mediated inputs produce less hyperpolarization and could even paradoxically depolarize the neuron (Coull et al., 2003 (Coull et al., , 2005 Prescott et al., 2006 ). This may be one possible mechanism that contributes to the production of allodynia and hyperalgesia associated with neuropathic pain. In contrast, the enhancement of the activity of glycinergic neurons exerts an antiallodynia in a nerve injury model (Abdin et al., 2006) . The evidence suggests the importance of glycinergic control of spinal pain processing. Extracellular concentrations of glycine at glycinergic nerve terminals are regulated by Na ϩ /Cl Ϫ -dependent glycine transporters (GlyTs). GlyT1 is widely expressed in glial cells. The evidence suggests an essential role of GlyT1 in lowering extracellular glycine concentration at the glycinergic synaptic cleft (Jursky and Nelson, 1996; Roux and Supplisson, 2000) . The inhibition of GlyT1 and enhancement of strychnine-sensitive glycine receptors would compromise the ability of GlyT1 inhibitors to be beneficial for pain control (Armer, 2000; Aragón and López-Corcuera, 2003) . On the other hand, GlyT1 prevents saturation of the glycine binding site on N-methyl-D-aspartate (NMDA) receptors and reduces the activity of excitatory synapses. The inhibition of this role of GlyT1 would counteract the ability of the GlyT1 inhibitor to be beneficial for pain control.
GlyT2 is largely localized to the presynaptic terminals of glycinergic neurons in the spinal cord as well as in the brain stem and cerebellum (Zafra et al., 1995a (Zafra et al., , 1995b . GlyT2 is present only in glycinergic neurons in association with postsynaptic glycine receptors; therefore, there is a concept that GlyT2 mediates the clearance of postsynaptically released glycine at the inhibitory synaptic cleft (Brasnjo and Otis, 2003) . It is expected that GlyT2 inhibitors would be useful in the treatment of pain by enhancing glycine receptor systems (Armer, 2000; Aragón and López-Corcuera, 2003) . However, several studies have shown that inhibition of GlyT2 by drugs or GlyT2-deficient mice did not significantly prolong or reduce the decay kinetics of glycinergic inhibitory postsynaptic currents in hypoglossal motoneurons (Singer et al., 1998; Oku et al., 1999; Gomeza et al., 2003b) . This may be explained by inefficient refilling of the synaptic vesicle with glycine by loss of GlyT2 function, resulting in decreased release of glycine. The evidence suggests that GlyT2 is essential for glycine uptake into the presynaptic cytosol for refilling synaptic vesicles with glycine rather than for clearing glycine at the glycinergic synaptic cleft (Eulenburg et al., 2005) ; therefore, whether GlyT2 inhibitors might be beneficial or detrimental to pain control is not clear.
In a recent study, several specific inhibitors of GlyTs have been developed. ORG25935 is a highly selective inhibitor of GlyT1 (IC 50 ϭ 100 nM) (Walker et al., 2001) . Sarcosine competitively inhibits GlyT1 (K i ϭ 30 -60 M) but not GlyT2 (K i Ͼ 1000 M) (López-Corcuera et al., 1998; Palacín et al., 1998) . ORG25543 is a highly selective inhibitor of GlyT2 (pIC 50 ϭ 7.8; IC 50 ϭ 16 nM) with negligible affinity for GlyT1 (pIC 50 Ͻ 4; IC 50 Ͼ100 M) and for the strychnine-sensitive glycine receptor (Caulfield et al., 2001) . ALX1393 is an inhibitor of GlyT2 (K i Ͻ1 M) (Xu et al., 2005; Luccini and Raiteri, 2007) . The present study was undertaken to examine whether GlyT inhibitors are effective to regulate nociceptive responses in neuropathic pain models.
Materials and Methods
Animal Models. Experiments were performed on adult male ddY mice that were 5 weeks old and weighed 25 to 30 g at the beginning of the study. Mice were housed at 22 Ϯ 2°C with free access to commercial food and tap water. All experimental procedures and animal handling were performed according to both the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society and the guidelines of Hiroshima University (Hiroshima, Japan). Mice were anesthetized with pentobarbital (60 mg/kg i.p.). Partial ligation of the sciatic nerve was performed by tying the distal one third to one half of the sciatic nerve, according to the procedure described in rats by Seltzer et al. (1990) and adapted to mice by Malmberg and Basbaum (1998) . In brief, the sciatic nerve was exposed at the high thigh level through a small incision and was carefully cleared of surrounding connective tissue just distal to the bony prominence of the femur. An 8-0 silk suture was inserted into the nerve with a three-eighths-curved, reversed-cutting mini-needle and tightly ligated so that the dorsal one-third to one-half of the nerve thickness was held within the ligature, and the wound was closed. In sham-operated mice, the nerve was exposed using the same procedure but without ligation. Diabetic mice were produced by an injection of streptozotocin (STZ) (200 mg/kg b.wt.) dissolved in 0.05 M sodium citrate buffer, pH 4.6, into the tail vein. The same volume of citrate buffer-injected agematched mice was used as a nondiabetic control group. One or 2 days after the injection of STZ, diabetes was confirmed by measuring urinary glucose with a Test-tape A (Shionogi Pharmaceutical, Osaka, Japan) and by measuring glucose concentration in a blood sample obtained from the tail vein with a GLUTEST E (Sanwa Chemical, Nagoya, Japan). Mice with blood glucose levels above 400 mg/dl were used as diabetic mice. The mechanical withdrawal threshold began to decrease significantly 3 days after STZ injection. The threshold of control and diabetic mice at 10 days after injection was 0.733 Ϯ 0.061 and 0.009 Ϯ 0.001 g (P Ͻ 0.0001), respectively. Allodynia presenting in diabetic mice persisted for 14 days after injection. The experiments were carried out 10 days after the injection of STZ or vehicle. For the preparation of complete Freund's adjuvant (CFA) model in mice, mice (n ϭ 6 -10/group) were lightly anesthetized with ether and received 20 l of CFA (1 mg/ml heatkilled Mycobacterium tuberculosis in 85% paraffin oil and 15% mannide mono-oleate) s.c. in the intraplantar surface of the right hindpaw. The control groups received 20 l of mineral oil in the ipsilateral paw. The dose of CFA produced a significant increase in paw volume and allodynia development (Ferreira et al., 2001; Kassuya et al., 2003) . CFA was injected 2 or 4 days before behavioral testing for allodynia as described above.
Measurement of Touch-Evoked Tactile Allodynia. Tactile allodynia was assessed by lightly stroking the injured leg with a paintbrush. Tactile allodynia response was ranked as described by Minami et al. (1995) : 0, no response; 1, mild squeaking with attempts to move away from the stroking probe; and 2, vigorous squeaking, biting the stroking probe, and strong efforts to escape from the stroking probe. Values are the average of the total score evaluated three times at each time point (possible maximal score at each time point, 2/mouse). In some experiments, tactile allodynia was evaluated by measuring the paw withdrawal threshold in response to probing with a series of calibrated fine filaments. Mice were further acclimated in individual clear Plexiglas boxes (9 ϫ 7 ϫ 11 cm) on an elevated wire mesh platform to allow access to the planter surface of the injured hindpaws. The von Frey filament was pressed perpendicularly against the mid-planter surface of the hindpaw from below the mesh floor and held for 3 to 5 s with it slightly buckled. The smallest filament that caused the animal to flinch or move the paw away from the stimulus five times out of five trials at intervals of 5 s was determined to be the mechanical threshold. The filament number was converted to buckling force (gram). Data analysis was conducted using analysis of variance and appropriate post hoc comparisons (P Ͻ 0.05). For assessment of allodynia, injection and observation of behavior were performed blind by different persons. Intrathecal (i.t.) injection was performed as described previously (Morita et al., 2004) .
Behavioral Tests. Spontaneous behaviors were assessed by posture, gait, activity of spontaneous movement, and defection. Locomotor activity in a novel environment was measured using a computerized locomotion detection system equipped with photosensors (SCANET MV-10MT; MATYS Co., Tokyo, Japan). Raising the glycine levels at spinal synapses in motor neurons should reduce spontaneous motor activity, as demonstrated in GlyT1-deficient mice (Gomeza et al., 2003a) . To test motor coordination and equilibrium, animals were placed on the rotating rod of the rotarod apparatus (Natume KN-75 RotaRod; Natume, Tokyo, Japan) on three successive days. For the rotarod assay, mice were allowed a 30-min acclimation period in the testing room. Two days after the mice were habituated to the rotarod, they were evaluated by the rotarod, where the rotational speed of the rod was kept constant at 8 rpm. Each session consisted of three 5-min trials a day, and each trial was separated by 30 min. The latency (seconds) to slip off the rod was automatically measured in each trial (maximal trial duration, 300 s). The average performance in three trials was used in data analyses. On the day of the experiment, the mice were given an i.t. or i.v. injection of GlyTs inhibitors (indicated doses) or artificial cerebrospinal fluid (ACSF)/saline (control group). After 3 h, the mice were placed on the rotating rod. The latency to fall from the rod was recorded. The test was repeated three times at the 30-min intervals. Dysfunction of GlyT2 is crucial for insufficient transmitter loading of synaptic vesicles in glycinergic nerve terminals. Hyperekplexia is a human neurological disorder characterized by exaggerated startle reflexes and muscle stiffness in the neonate and is typically caused by mutations in the gene encoding glycine receptor (GlyR)␣ 1. In recent studies, mutations have been found in the gene encoding GlyT2 (SLC6A5), resulting in defective GlyT2 function of hyperekplexia patients Rees et al., 2006) . Hindfeet clenching is associated with dominant hyperekplexia (Becker et al., 2002) . Qualitatively, motor deficiencies in animals were recognized by handling. Display of hindfeet clenching or limb clenching when picked up by the tail was determined. Righting time was determined after bringing the animals into a supine position as described previously (Hartenstein et al., 1996; Becker et al., 2000) .
Knockdown of GlyT1, GlyT2, and GlyR␣3 in the Spinal Cord. Knockdown of GlyR␣3 was performed as described previously (Morita et al., 2008) . The hemagglutinating virus of the Japan (HVJ) envelope vector system (HVJ Envelope Vector Kit GenomONE; Ishihara Sangyo Kaisha, Ltd., Osaka, Japan) was used for in vivo small interfering RNA (siRNA) transfer. This HVJ-Envelope Vector has proven to be an effective oligodeoxynucleotide delivery system both in vitro and in vivo (Kaneda et al., 2002) . siRNAs were incorporated into the HVJ-Envelope Vector according to the manufacturer's instructions. In brief, after mixing 40 l (1 assay unit) of HVJ-Envelope Vector with 4 l of the enclosing factor, the mixture was centrifuged (10,000g, 10 min, 4°C), and the pellet was suspended in 10 l of buffer solution. Then, 10 l of a mixture of three siRNAs solution (nos. 1, 2, and 3; 1 g/l each) was added, and the mixture was kept on ice for 5 min. Sterile ACSF (10 l) containing synthetic siRNA duplexes (0.45 pmol/ animal) was injected into the subarachnoid space between the L 5 and L 6 vertebrate of conscious mice. The sequences of siRNA (sense) were as follows: GlyT1 (no. 1, 5Ј-GCUGUCAGACGACAUUGGAAACUUU-AG-3Ј; no. 2, 5Ј-GCAACCAGAUCGAGUUUGUACUGAC-AG-3; no. 3, 5Ј-GAGUGGAUUCUGCAGAAGAAGACCU-AG-3Ј; no. 4, 5Ј-GCUAU-CAGACGACAGUGGACACUGU-AG-3); GlyT2 (no. 1, 5Ј-GGAACA-CACCAGAAUGCAAAGAUAA-AG-3Ј; no. 2, 5Ј-GCGAAAGGAAUU-AAGUCAUCAGGAA-AG-3Ј; no. 3, 5Ј-CCCAAGAUACAGAUCAAGAAC-UCUA-AG-3Ј; no. 4, 5Ј-GGAGCACACUAGAAUGCACAGAUAG-AG-3Ј); GlyR␣3 (no. 1, 5Ј-AGGUUUCGGCGAAAGAGAAAGAAUA-AG-3Ј; no. 2, 5Ј-GGUACUGCACUAAACACUACAAUAC-AG-3Ј; no. 3, 5Ј-CCUUAG-GCAUGAAGACAUUCAUCAU-AG-3Ј; no. 4, 5Ј-GAUACUGCACUA-CACACUACGAUAC-AG-3Ј). At the times indicated in the text, mice were anesthetized with pentobarbital, and the spinal cords were subjected to immunoblotting analysis. In the controls, we followed the same procedures; however, we substituted an identical amount of mismatched siRNA no. 4 with HVJ-Envelope Vector and only the HVJEnvelope Vector without siRNA.
Western Blot Analysis. The lumbar regions of spinal cord (L 2 -L 6 ) were obtained from untreated animals or animals receiving injections with HVJ-Envelope Vector, GlyR siRNA, or the mutant siRNA. The spinal cord tissues (4.8 -5.0 mg) were homogenized in 20 mM Tris-HCl, pH 7.5, containing 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 10 mM ␤-glycerophosphate, and 1 g/ml of the various protease inhibitors (benzamidine, leupeptin, and antipain). The homogenate was reacted with 0.6% Nonidet P40 for 5 min at 4°C followed by centrifugation at 15,000 rpm for 5 min at 4°C, and the supernatant was obtained. The supernatant was mixed at a volume ration of 4:1 in 10 mM Tris-HCl, pH 6.8, containing 10% (v/v) glycerol, 2% SDS, 0.01% bromophenol blue, and 0.5% ␤-mercaptoethanol, with subsequent boiling at 100°C for 10 min.
To detect GlyT1, GlyT2, and GlyR␣3, tissue lysates (30 g of crude protein extracts/line) were electrophoresed on a polyacrylamide gels (stacking gel 3% and separating gel 10%), transferred onto polyvinylidene fluoride membranes, and Western blotted. The primary antibodies were as follows: against GlyT1 (Alpha Diagnostic International, San Antonio, TX); GlyT2 (Alpha Diagnostic International); GlyR␣3 (Sigma-Aldrich, St. Louis, MO). The secondary antibodies were as follows: for GlyT1 and GlyT2 antibodies, anti-rabbit IgG antibody conjugated with horseradish peroxidase (Dako Denmark A/S, Glostrup, Denmark); for GlyR␣3 antibody, biotinylated panspecific secondary antibody (Vector Laboratories, Burlingame, CA).
To detect ␤-actin, lysates (15 g of crude protein extracts/line) were separated on a 10% SDS-polyacrylamide gel, transferred onto polyvinylidene fluoride membranes, and Western blotted. Blots were incubated with primary antibodies against ␤-actin obtained from IMGENEX Innovations in Functional Genomics (San Diego, CA), and the secondary anti-rabbit IgG antibody conjugated with horseradish peroxidase was obtained from Dako Denmark A/S. All Western blots were developed using Hyperfilm ECL and the ECL kit (GE Healthcare, Chalfont St. Giles, UK) according to the manufacturer's instructions followed by exposure to X-ray films. Densitometry was carried out on these X-ray films with the aid of an ATTO Densitograph 4.0 (Atto Corporation, Tokyo, Japan).
Materials. ALX1393, DCK, gabapentin, L-701,324, and sarcosine (N-methyl glycine) were obtained from Sigma-Aldrich. ORG25543 and ORG25935 were donated by Organon Laboratories Ltd. (Scotland, UK). ALX1393 was dissolved in a solvent containing 25% 2-hydroxypropyl-␤-cyclodextrin (Sigma/RBI, Natick, MA) and distilled water, and pH was adjusted to ϳ6 using 1 N NaOH. DCK and L-701,324 were dissolved in dimethyl sulfoxide and diluted appropriately (final concentration of dimethyl sulfoxide was 0.1%). Other reagents were dissolved in ACSF or saline. ACSF composition was 142 mM NaCl, 5 mM KCl, 2 mM CaCl 2 ⅐2H 2 O, 2 mM MgCl 2 ⅐6H 2 O, 1.25 mM NaH 2 PO 4 , 10 mM D-glucose, and 10 mM HEPES, pH 7.4. tion of GlyT1 inhibitors ORG25935 and sarcosine decreased the allodynia score and ameliorated the reduction of the withdrawal threshold in a partial sciatic nerve ligation-injury model (Fig. 1, A and B) . This effect appeared after a time lag of approximately 1.5 to 2 h after injection of the drug. Intravenous injection of GlyT2 inhibitors ORG25543 and ALX1393 ameliorated allodynia, and this antiallodynia effect appeared without a time lag after injection of the drugs (Fig.  1, C and D) . Both GlyT1 and GlyT2 inhibitors ameliorated allodynia by i.t. injection, and the effect was more potent and longer than that of gabapentin as shown in ED 50 values and the duration of action (ED 50 estimated by the withdrawal threshold for ORG25935, ORG25543, and gabapentin were 5.3, 11.0, and 8200 ng/mouse, respectively) ( Table 1 ). The inhibitors of GlyT1 and GlyT2 ameliorated mechanical allodynia in other neuropathic pain models such as the STZinduced diabetic model. Dose-response effects of ORG25935 showed that the antiallodynia effect peaked by i.t. injection of 3 to 300 ng in the partial sciatic nerve injury model and showed a bell-shaped effect with a peak effect at 0.1 mg/kg by i.v. injection at 10 g to 10 mg/kg in the STZ diabetic model, whereas ORG25543 showed a dose-dependent antiallodynia effect in this dose range (Table 1) . Antiallodynia effects of GlyTs inhibitors are relatively less in the CFA-induced chronic inflammation model (Table 1) . To further confirm the specific inhibition of GlyT1 and GlyT2 exerting an antiallodynia effect, the effect of knockdown of GlyTs by siRNA of GlyTs mRNA on tactile allodynia was examined. A significant reduction of GlyT1 and GlyT2 expression in the spinal cord of mice treated with GlyT siRNA with HVJ-Envelope Vector compared with untreated mice that received HVJEnvelope Vector injections or control mice that received mutant siRNA injections was confirmed by Western blot analysis 3 days after treatment (Fig. 2, A and B) . On the 10th day after surgery, introduction of either GlyT1 siRNA (Fig. 2C ) or GlyT2 siRNA (Fig. 2D) into the spinal cord ameliorated allodynia, as shown by reduction of the allodynia score and recovery from the decreased withdrawal threshold from 2 to 7 days for GlyT1 siRNA or 2 to 9 days for GlyT2 siRNA after introduction. HVJ-Envelope Vector or GlyT siRNA mutants had no effect (data not shown). No apparent behavioral change was observed during this period. 
Results
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Phenotypic Characteristics by Blockade of GlyTs and GlyRs. All of the GlyT inhibitors with doses displaying antiallodynia effects or even higher doses, either by i.v. or i.t. injection, had no effect on spontaneous behaviors, locomotor activity, the withdrawal threshold in normal mice, and motor behavior in the rotarod test (Table 2 ). These treatments did not disturb the righting reflex and did not produce hindlimb disorder, which are typical behaviors of hyperekplexia (Table   2 ). Strychnine produces hindlimb disorder at 9 g i.t., which was much higher than doses used to block the antiallodynia effect of GlyT2 inhibitors ( Table 2) .
Effects of Antagonists of the NMDA Glycine Site on the Effects of GlyT1 Inhibitors. The present study demonstrated that GlyT1 inhibitors ORG25935 and sarcosine, but not GlyT2 inhibitors ORG25543 and ALX1393, required a lag time before onset of the effect. To explore whether these effects of GlyT1 inhibitors are due to the action of glycine on the NMDA receptor and subsequent activation of the receptor function, the effects of inhibitors on the NMDA glycine binding site, L-701,324 and DCK, were examined. ORG25935, but not ORG25543, by itself produced a slight and transient reduction of the withdrawal threshold in sham-operated mice (Fig. 3A) . Pretreatment of L-701,324 or DCK protected ORG25935 from reduction of the withdrawal threshold (Fig.  3A) . L-701,324 abolished the lag time of ORG25935 to reduce the withdrawal threshold, and it prolonged the antiallodynia effect in a partial sciatic nerve ligation-injured model (Fig.  3B) . Therefore, the activation of NMDA receptors by increased glycine through the inhibition of GlyT1 by GlyT1 inhibitors may delay the onset of and counteract the antiallodynia effect of GlyT1 inhibitors.
Effect of Blockade of Glycine Receptors by Strychnine or Knockdown of GlyR␣3 by siRNA on Antiallodynia Effect of GlyT Inhibitors.
To confirm that the antiallodynia effect of ORG25935 and ORG25543 is due to the inhibition of GlyTs and the subsequent activation of postsynaptic glycine receptors, the effect of strychnine, an inhibitor of glycine receptors, and knockdown of GlyR␣3 was examined. The antiallodynia effects of i.v. injected ORG25935 and ORG25543 were reversed by intrathecal injection of strychnine at 5 h (Fig. 4A) , 1, 2, and 3 days (Fig. 4, C and D) after the injection of GlyT inhibitors. Strychnine at the doses used, or even 10 ng i.t., did not significantly reduce the withdrawal threshold (Fig. 4B ) and did not produce any sign of convulsions ( Table 2 ). The antiallodynia effect of gabapentin, the mechanisms of which do not involve the glycinergic system, was not reversed by strychnine (data not shown). These results suggest that GlyT inhibitors, injected systemically, act through the activation of glycinergic receptors in the spinal cord for antiallodynia action. GlyR␣3 is specifically expressed in the superficial dorsal horn, whereas GlyR␣ 1 is widely distributed in the dorsal horn. To explore the target Fig. 2 . Knockdown of GlyT1 and GlyT2 by siRNA ameliorated mechanical allodynia assessed after partial sciatic nerve ligation injury in the mice. A and B, Western blot analysis of spinal GlyT1 (A) and GlyT2 (B) after transfection of siRNAs for GlyT1 and GlyT2 into the spinal cord of mice. As controls, HVJ-Envelope Vector (HVJ-E) or mutant siRNA was injected into the spinal cord. The levels of GlyT1 and GlyT2 were normalized to ␤-actin and represented as percentage induction compared with the values of untreated mice. Data are expressed as the mean percentage of naive control Ϯ S.E.M. (n ϭ 4 -8 mice per group). ‫,ء‬ P Ͻ 0.05 compared with the corresponding control, as determined by analysis of variance followed by Fisher's protected least significant difference test. C and D, effects of treatment with GlyT1 siRNA and mutant siRNA (C) or GlyT2 siRNA and mutant siRNA (D) on mechanical allodynia assessed after partial sciatic nerve ligation injury in mice. The experiments were carried out 10 days after nerve ligation. ‫,ء‬ P Ͻ 0.01 compared with the corresponding control, as determined by analysis of variance followed by Tukey's test.
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molecule for GlyT inhibitors to induce antiallodynia, the effect of knockdown of the GlyR␣3 subunit by siRNA on the antiallodynia effect of GlyT inhibitors was examined. Significant reduction of GlyR␣3 expression during 1 to 5 days with a peak reduction at 3 days after treatment with GlyR␣3 siRNA in the spinal superficial layers of mice compared with untreated mice that received HVJ-Envelope Vector injections or control mice that received mutant siRNA injections was confirmed by immunohistochemical and Western blot analysis (Morita et al., 2008) . Both ORG25935 (Fig. 4E) and ORG25543 (Fig. 4F) by i.v. injection failed to ameliorate the allodynia response in nerve-injured mice that were transfected with siRNA of GlyR␣3, whereas they produced an antiallodynia effect in mice that received injections with HVJ-Envelope Vector or mutant siRNA.
Timing of the Treatment of GlyT Inhibitors. GlyT2 is suggested to play a role to supply glycine to synaptic vesicles in nerve terminals of glycinergic neurons rather than to clear glycine in the synaptic cleft from the observation of tissues from GlyT2-deficient mice or in in vitro experiments with continuous exposure of GlyT2 inhibitors to tissues from normal animals. If this occurred in glycinergic neurons that regulate sensory neurons in the spinal cord in vivo, the repeated administration of GlyT2 inhibitors would result in the reduction of glycine release and thus decrease the antiallodynia effect. However, this may not have occurred in the present case, because six repeated injections of ORG25543 every 4th day produced an antiallodynia effect with similar potency (Fig. 5) . The antiallodynia effect of ORG25543 at 1 day after the 6th injection was antagonized by the i.t. injection of strychnine, suggesting a continuous antiallodynia effect that is mediated by stimulation of glycine receptors even after repeated treatment with GlyT2 inhibitors.
It has been suggested that different mechanisms mediated a Total amount of locomotor activity in 60 min after inhibitors of GlyTs and specific siRNA of GlyTs. There were no significant differences between animals pretreated with vehicle and with mutant siRNA. All values represent the mean locomotor activity in 60 min Ϯ S.E.M.
b The intensity of mechanical allodynia was as follows: Ϫ, score 0 -0.5; ϩ, score 0.5-1; ϩϩ, score 1-1.5; ϩϩϩ, score 1.5-2. c Seizures induced by drugs were characterized by ataxia, brief loss of the righting reflex, and clonic and tonic convulsions. The percentage of animals that exhibited convulsions in each treatment group was determined.
d The time required to right after being turned on to its back. Ͻ1: less than 1 s. e Hindfeet clenching or limb clenching phenotype when picked up by the tail. Ϫ, negative; ϩ, positive. by a variety of neuronal and neighbor cells, various neurotransmitters, and mediators may be diversely concerned in the stage of formation of neuropathic pain, such as the initiation, development, and maintenance of allodynia. Although GlyT inhibitors had an excellent antiallodynia effect on established allodynia, it would be of more value if they could protect against the formation of neuropathic pain when treated in the early phase of nerve injury. However, when ORG25543 was treated before surgery, or 1 and 2 days after surgery, it never recovered the reduced withdrawal threshold during the 3 days after surgery. However, these treatments started to ameliorate the reduced withdrawal threshold after the 4th day postsurgery, regardless of the different timing of injection (Fig. 6A) . The effects of knockdown of GlyT2 on the time-dependent appearance of allodynia after nerve injury was also examined. For this purpose, siRNA for GlyT2 mRNA was injected into the spinal cord two times at 3 days and 3 h before surgery to maintain the reduced expression of GlyT2. These treatments did not ameliorate the reduced withdrawal threshold during the 2 days after surgery, but the withdrawal threshold started to increase at 3 days and ameliorated at 4 days after surgery (Fig. 6B) . These results suggest that even when the expression of GlyT2 protein was reduced, an allodynia response appeared during the 3 days postsurgery and became effective after 3 days, as shown by the increased threshold on the 3rd to 4th day. Re-reduction of the threshold on the 5th day may be due to recovery of the expression of GlyT2 protein. The treatment of siRNA on the 5th as well on the 15th day after surgery produced a profound antiallodynia effect (Fig. 6B) . Mutant siRNA had no effect at any injection. Similar results were obtained with the injection of ORG25935 and GlyT1 knockdown (Fig. 6, C and D) . The results clearly showed that the inhibition of GlyTs did not prevent the initiation of allodynia by sciatic nerve ligation, and it did not antagonized the allodynic response during the early pathological stage. The present evidence that GlyT inhibitors lack an inhibitory effect on allodynia in the early stage of allodynia development after nerve injury, whereas they produce potent and long-acting antiallodynia action against established allodynia, may suggest that glycinergic inhibitory control is disordered in the early stage of developing allodynia after nerve ligation. Strychnine, a glycine receptor antagonist, ameliorated allodynia at 20 h and 3 days after surgery, whereas it had no effect after 4 days postsurgery in the partial sciatic nerve ligation-injury model (Fig.  6E) . Again, when GlyR␣3 was knocked down by the injection of siRNA for GlyR␣3 mRNA at 3 days and 3 h before surgery on the sciatic nerve, allodynia was not initiated during the first 3 days after surgery, and then reduction of the withdrawal threshold occurred on the 4th day (Fig. 6F) . Injection of siRNA on the 5th and 13th day after surgery had no effect (Fig. 6F) . Thus, glycinergic neuronal activity reversed the control of pain signal transduction, depending on the development stage of neuropathy: exacerbation in the early stage and reduction in the late stage. In agreement with this concept, bicuculline, a GABA A receptor antagonist, also produced an antiallodynia effect within 3 days, and this effect was reversed by isoguvacine, a GABA A receptor agonist (Fig.  6G ). Bicuculline lost its action after the 4th day postsurgery (Fig. 6G ). Isoguvacine produced antiallodynia, which was sensitive to bicuculline antagonism only after the 4th day postsurgery (Fig. 6H) . Of great interest, all of the data showed that the critical turning point of the reverse inhibitory regulation seemed to be between the 3rd and 4th day after surgery.
Antiallodynia and Glycine Transporter
Discussion
The present study demonstrated a profound and long-lasting antinociceptive effect of the inhibitors of GlyT1 and GlyT2 in partial sciatic nerve ligation-induced neuropathic pain models, STZ-induced diabetic models, and with less potency in the CFA-induced inflammatory model in mice. Their different potency among the models may be due to the diverse mechanisms involved in the development of chronic pain in each model, especially between neuropathic pain and inflammation.
Considering the role of GlyT1 to lower extracellular glycine concentration at the glycinergic synaptic cleft (Jursky and Nelson, 1996; Roux and Supplisson, 2000; Cubelos et al., 2005) , the antiallodynia effect of GlyT1 inhibitors ORG25935 and sarcosine, due to the blockade of glycine uptake, mostly by glial cells and partly by neurons, resulted in the accumulation of glycine at the site of GlyRs, which suppress the excitatory neuronal activity of target neurons for noxious signal transduction in the spinal cord. It is noteworthy that the antiallodynia effect of GlyT inhibitors lasted all day and was antagonized by i.t. injection of strychnine at any time, such as 1, 2, or 3 days after the i.v. injection of GlyT inhibitors. The evidence suggests that these inhibitors by single i.v. injection may produce an antiallodynia effect by stimulating glycine receptors at the spinal cord during the effective term. The possibility that these compounds irreversibly block GlyTs during the period and/or thus cause down-regulation of the expression of GlyTs in the plasma membrane still remains to be elucidated. A limitation point of GlyT1 inhibitors as analgesics is the lag time of 1 to 2 h required after administration before developing an antiallodynia effect, which was partly masked due to saturation of the glycine binding site on NMDA receptors by inhibiting glycine uptake with GlyT1 inhibitors, as shown by the specific antagonists of NMDA receptor glycine site, L-701,324, or DCK, completely abolishing this lag time and potentiating the GlyT1 inhibitorinduced antiallodynia effect. This explanation was supported by the ability of ORG25935, but not ORG25543 by i.t. injection itself, to produce slight and transient reduction of the withdrawal threshold, which was inhibited by L-701,324 and DCK. The observations that the potency of the antiallodynia effect of high dosages of ORG25935 decreased and the period of the antiallodynia effect by GlyT1 knockdown was shorter than that of GlyT2 knockdown also suggest a counteracting effect by the stimulation of NMDA receptors in the spinal cord and higher brain regions at higher doses of GlyT1 inhibitors, although the time-dependent changes of GlyT1 protein expression were similar to those of GlyT2. In fact, microdialysis perfusion of the lumbar dorsal spinal cord of rats reveals that ORG24598, a selective inhibitor of GlyT1, increases extracellular glycine accompanied by a progressive increase in citrulline, which resulted from activation of the NMDA receptor/nitric oxide synthase signaling cascade (Whitehead et al., 2004) . GlyT1 is distributed widely in the central nervous system and may have a role in controlling concentrations of glycine in the vicinity of NMDA receptors. This affords an opportunity for GlyT1 inhibitors to enhance NMDA receptor function and may have relevance in addressing the hypoglutamatergic function associated with schizophrenia or depression (Tsai et al., 2004; Gomeza et al., 2006) . This effect may have the desired effect for the use of these compounds as analgesics in such psychotic patients, or undesired otherwise.
The restricted presence of GlyT2 in glycinergic neurons suggests its important role in the control of glycinergic neurotransmission (Jursky and Nelson, 1995) ; however, evidence supports the fact that GlyT2 does not seem to play an important role in clearing the glycinergic synaptic cleft. GlyT2 inhibitors do not affect the decay kinetics of glycinergic inhibitory synaptic potentials (IPSPs) in rat brain stem motoneurons (Titmus et al., 1996; Singer et al., 1998) . Hypoglossal motoneurons from GlyT2-deficient mice are shown to display glycinergic miniature IPSPs (mIPSPs) with a marked reduction in amplitude compared with those recorded from wild-type mice (Gomeza et al., 2003b) and those from GlyT1-deficient mice, in which the decay time constant of glycinergic mIPSPs was longer than that in wild-type mice (Gomeza et al., 2003a) . GlyT2 presents in glycinergic boutons adjacent to active zones (Spike et al., 1997) ; thus, it has been suggested that GlyT2 plays an important role in taking up glycine to refill synaptic vesicles with glycine and to maintain exocytotic release of glycine in response to nerve stimulation (Singer et al., 1998; Oku et la., 1999; Gomeza et al., 2003b) . In this case, the inhibition of GlyT2 function would be expected to deteriorate nociceptive mechanisms. However, Bradaïa et al. (2004) demonstrated, using whole-cell voltage clamp recording from lamina X neurons in rat spinal cord slices, that ORG25543 as well as ORG24598, a GlyT1 inhibitor, increase the decay time constants of miniature, electrically evoked and spontaneous IPSPs, although ORG25543 decreased the frequency of mIPSP. The authors conclude that blocking glial and/or neuronal glycine transporters increased the level of glycine in the spinal cord, which in turn prolonged the duration of the glycinergic synaptic current. An increase in extracellular glycine without accompanying citrulline release was demonstrated by microdialysis perfusion with ORG25543 of the lumbar dorsal spinal cord of rats (Whitehead et al., 2004) . Evidence suggests that the pharmacological blockade of GlyT2 increases either glycinergic and/or GABAergic neurotransmission in vivo in the spinal cord. The present evidence shows that the antiallodynia effect of systemically administered (i.v.) GlyT2 inhibitors was counteracted by i.t. injection of strychnine or knockdown of spinal GlyR␣3, suggesting mediation by the activation of spinal GlyR␣3 of the antiallodynia effect of GlyT2 inhibitors.
The antiallodynia effect of GlyT2 inhibitors ORG25543 and ALX1393 appeared without a time lag after administration. ORG25543 showed a dose-dependent antiallodynia effect with the same dose range as ORG25935, which was effective in a limited dose range. Together with the confined distribution and highest densities of GlyT2 in boutons in lamina III of dorsal horn in comparison with the distribution of GlyT1 in astrocytes in lamina I and II in the spinal cord (Zafra et al., 1995a) , these results suggest that there are fewer side effects of these compounds. However, the deletion of mouse GlyT2 results in a hyperekplexia phenotype (Gomeza et al., 2003b) . Thus, dysfunction of GlyT2 function is crucial for insufficient transmitter loading of synaptic vesicles in glycinergic nerve terminals. However, there was no sign of hyperekplexia by the administration of GlyT2 inhibitors. Again, strychnine required approximately 3000 times higher doses to produce hindlimb disorder than those for blocking the antiallodynia effect of GlyT2 inhibitors. Thus, it seems possible that glycinergic control of signal transduction in sensory nerves is more sensitive to manipulation by drugs than that in motor neurons. Therefore, it does not seem probable that GlyT2 inhibitors by treatment for pain control may produce hyperekplexia-like disorders. In addition, reproduction of the antiallodynia effect by repeated treatment of ORG25543 (i.v.) with similar potency each time suggests that glycine refilling was not impaired in glycinergic nerve terminals by pharmacological manipulation in vivo. Tricyclic antidepressants are one of the major clinical medicaments for neuropathic pain, and some can inhibit GlyTs. Sarcosine blocks GlyT1 (Morrow et al., 1998) , and amoxapine inhibits GlyT2 more selectively (Nú ñ ez et al., 2000) . Doxepin, amitriptyline, and nortriptyline block both GlyT1 and GlyT2 (Nú ñ ez et al., 2000) . We have achieved the knockdown of spinal GlyT1 and GlyT2 in vivo by introducing the corresponding siRNAs into the mouse spinal cord. Evidence that either knockdown of GlyT1 or Fig. 6 . Postsurgery period time-dependent antiallodynic effect of GlyT inhibitors, GlyT knockdown, strychnine, bicuculline, and isoguvacine in partial sciatic nerve ligation-injury mice. Mechanical allodynia was assessed in mice using von Frey hairs on ipsilateral paws. A, ORG25543 and ORG25935 (C) were administered i.v. 1 day and 30 min before surgery and 2 and 4 days postsurgery. B, siRNA or mutant siRNA of GlyT2 mRNA and siRNA (D) or mutant siRNA of GlyT2 mRNA were injected into the spinal cord 3 days and 3 h before and 5 and 15 days after nerve ligation. E, strychnine was injected i.t. 1, 3, 4.5, or 13 days after nerve ligation. F, siRNA or mutant siRNA of GlyR␣3 mRNA was injected into the spinal cord 3 days and 3 h before or 5 and 12 days after nerve ligation. G, bicuculline was injected i.t. 1.5, 3, 4.5, or 12 days after nerve ligation. Isoguvacine (Isg) was injected 40 min after the injection of bicuculline. H, isoguvacine was injected i.t. 1.5, 3, 4.5, or 12 days after nerve ligation. Bicuculline (Bicu) was injected 40 min after isoguvacine injection. Data are expressed as the mean Ϯ S.E.M. n ϭ 5-10 mice per group.
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GlyT2 effectively ameliorated allodynia further supports the antiallodynia effect by inhibition of GlyTs.
It is interesting to not that with pretreatment or treatment immediately after surgery in a nerve injury model, both GlyT1 and GlyT2 inhibitors failed to produce an antiallodynia effect until 4 days after surgery; therefore, it is assumed that glycinergic inhibitory controls are impaired in this early stage of the development of neuropathic pain. Recent attention has focused on relief from the inhibitory systems of spinal neurons as a mechanism for neuropathic pain. Coull et al. (2003) demonstrated that the reduced expression of K ϩ Cl Ϫ (KCC) cotransporter, KCC2, reduced anion reversal potential in spinal lamina I neurons in the dorsal spinal cord after peripheral nerve injury. The change in the driving force means that both glycine and GABA A receptormediated inputs produce less hyperpolarization and could even paradoxically depolarize neurons (Coull et al., 2005; Prescott et al., 2006) . This contributes to the cellular hyperexcitability producing allodynia after peripheral nerve injury.
The present evidence that glycine receptor blockade by strychnine or knockdown of the GlyR␣3 or GABA A receptor antagonist bicuculline inhibited the development of tactile allodynia in the early stage postsurgery suggests that the activation of glycinergic receptors, especially GlyR␣3 and GABA A receptors, may lead to the induction of allodynia. There was the critical turning point at 3 to 4 days postsurgery; stimulation of the glycinergic system by GlyT inhibitors and knockdown of GlyTs or stimulation of the GABAergic system by GABA A receptor agonist isoguvacine started to ameliorate allodynia after 4 days postsurgery. It is also suggested that blockade of the excitatory influence of glycinergic and GABAergic systems in the early stage cannot cure the pathological cause, because allodynia developed after the 4th day postsurgery under continuous treatment. Coull et al. (2005) have proposed that microglia and neuron interaction via brain-derived neurotrophic factor released from microglia through TrkB leads to a reduction of the expression of KCC2 and a depolarization shift in the anion reversal potential in the spinal cord. Reduction of the anion reversal potential in spinal lamina I neurons in the dorsal spinal cord in the present model and glycine and GABA A receptor-mediated depolarization of the neurons as a function of time after peripheral nerve injury remain to be confirmed.
In summary, the present study demonstrated that the inhibition of GlyT1 and GlyT2 produced an antiallodynia effect in neuropathic pain models in mice. This effect was potent and long-lasting. The mechanism of their antiallodynia action was enhancement of the glycinergic inhibitory pathway through GlyR␣3 in the spinal cord. Therefore, GlyTs seem to be a hopeful target for the development of medicaments for neuropathic pain. The present study also implied that the timing of medication is very important. Reversal of the inhibitory regulation of glycinergic and GABAergic systems to excitatory regulation at a critical point 3 to 4 days postsurgery also provided important information for understanding the underlying molecular mechanisms of the development of neuropathic pain.
